Immunogenicity and Reactogenicity of an Inactivated SARS-CoV-2 Vaccine (BBV152) in Children Aged 2–18 Years: Interim Data from an Open-Label, Non-randomised, Age De-escalation Phase 2/3 Study

Scientists conducted an age de-escalation study to assess the safety, reactogenicity, and immunogenicity of an inactivated COVID-19 vaccine, BBV152, in children aged 2-18 years.

[Lancet Infectious Diseases]